Delivery Order SPE2DB20D1109-SPE2DB24FP76T
Award Date
8/23/24
Potential Completion Date
8/26/24
Potential Value
$5.1K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract is a Delivery Order issued by the Defense Logistics Agency (DLA), a defense agency, with a Ceiling Value of $1,971.60 and a completion date of June 6, 2024. This is a Firm Fixed Price contract. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,521.26 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of June 25, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order for the medication HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract has a ceiling value of $1,684.96 and is a Firm Fixed Price contract with the Defense Logistics Agency (DLA), a defense agency. The contract is not designated as a set-aside and has an ultimate completion date of July 7, 2025. Amerisourcebergen Drug Corp is the prime contractor and is responsible for delivering...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $110,730.45 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has a final completion date of September 9, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025. This IDC...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The $8,424.80 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract has a completion date of July 8, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading global pharmaceutical distributor Amerisourcebergen Corporation. The $27,996.72 contract is for the supply of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing a wide range of pharmaceutical products...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,148.05 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The contract has an ultimate completion date of March 25, 2024 and does not utilize any set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued up to $999,999,999.00 through December 31,...
This federal contract award, valued at $18,927.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is a Delivery Order for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of May 29, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $3,154.56 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and is in effect through December 2025. The...